Anti-interleukin-6 receptor antibody prevents systemic bone mass loss via reducing the number of osteoclast precursors in bone marrow in a collagen-induced arthritis model

Clinical and Experimental Immunology

Volumn 175, Issue 2, 2014, Pages 172-180

  Tanaka, Keisuke ^a   Hashizume, Misato ^a   Mihara, Masahiko ^a   Yoshida, Hiroto ^a   Suzuki, Miho ^a   Matsumoto, Yoshihiro ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Collagen induced arthritis; Interleukin 6; Osteoclast; Sphingosine 1 phosphate receptor 2

Indexed keywords

INTERLEUKIN 6 ANTIBODY; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; SPHINGOSINE 1 PHOSPHATE RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BLOOD; BONE MARROW; BONE MASS; CELL MIGRATION; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

COLLAGEN-INDUCED ARTHRITIS; INTERLEUKIN-6; OSTEOCLAST; SPHINGOSINE-1-PHOSPHATE RECEPTOR 2;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, EXPERIMENTAL; BONE DENSITY; BONE MARROW CELLS; BONE RESORPTION; CELL MOVEMENT; COLLAGEN; GENE EXPRESSION; INFLAMMATION; INTERLEUKIN-6; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, INBRED DBA; OSTEOCLASTS; RECEPTORS, INTERLEUKIN-6; RECEPTORS, LYSOSPHINGOLIPID; RNA, MESSENGER; SPHINGOSINE; STEM CELLS;

EID: 84891587770     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12201     Document Type: Article

References (38)

1. Shibuya K, Hagino H, Morio Y, Teshima R. Cross-sectional and longitudinal study of osteoporosis in patients with rheumatoid arthritis. Clin Rheumatol 2002; 21:150-158.
2. Lacey DL, Timms E, Tan HL etal. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165-176.
3. Kong YY, Yoshida H, Sarosi I etal. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397:315-323.
4. Dougall WC, Glaccum M, Charrier K etal. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13:2412-2424.
5. Li J, Sarosi I, Yan XQ etal. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000; 97:1566-1571.
6. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 2009; 5:667-676.
7. Yu X, Huang Y, Collin-Osdoby P etal. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res 2003; 18:1404-1418.
8. Wright LM, Maloney W, Yu X etal. Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts. Bone 2005; 36:840-853.
9. Koizumi K, Saitoh Y, Minami T etal. Role of CX3CL1/fractalkine in osteoclast differentiation and bone resorption. J Immunol 2009; 183:7825-7831.
10. Kim MS, Day CJ, Morrison NA. MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J Biol Chem 2005; 280:16163-16169.
11. Choi SJ, Cruz JC, Craig F etal. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000; 96:671-675.
12. Lean JM, Murphy C, Fuller K etal. CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts. J Cell Biochem 2002; 87:386-393.
13. Ha J, Choi HS, Lee Y etal. CXC chemokine ligand 2 induced by receptor activator of NF-kappa B ligand enhances osteoclastogenesis. J Immunol 2010; 184:4717-4724.
14. Kwak HB, Ha H, Kim HN etal. Reciprocal cross-talk between RANKL and interferon-gamma-inducible protein 10 is responsible for bone-erosive experimental arthritis. Arthritis Rheum 2008; 58:1332-1342.
15. Binder NB, Niederreiter B, Hoffmann O etal. Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis. Nat Med 2009; 15:417-424.
16. Ishii M, Egen JG, Klauschen F etal. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 2009; 458:524-528.
17. Ishii M, Kikuta J, Shimazu Y etal. Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo. J Exp Med 2010; 207:2793-2798.
18. Le Goff B, Soltner E, Charrier C etal. A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. Arthritis Res Ther 2009; 11:R185.
19. Hayashi I, Hagino H, Okano T etal. Effect of raloxifene on arthritis and bone mineral density in rats with collagen-induced arthritis. Calcif Tissue Int 2011; 88:87-95.
20. Yoshida H, Hashizume M, Mihara M. IL-6 blockade preferentially inhibits Th17 differentiation in collagen-induced arthritis. Rheumatol Int 2011; 31:127-131.
21. Okazaki M, Yamada Y, Nishimoto N etal. Characterization of anti-mouse interleukin-6 receptor antibody. Immunol Lett 2002; 84:231-240.
22. Barou O, Valentin D, Vico L, Tirode C, Barbier A etal. High-resolution three-dimensional micro-computed tomography detects bone loss and changes in trabecular architecture early: comparison with DEXA and bone histomorphometry in a rat model of disuse osteoporosis. Invest Radiol 2002; 37:40-46.
23. Ruegsegger P, Koller B, Muller R. A microtomographic system for the nondestructive evaluation of bone architecture. Calcif Tissue Int 1996; 58:24-29.
24. Uchiyama T, Tanizawa T, Muramatsu H, Endo N, Takahashi HE etal. A morphometric comparison of trabecular structure of human ilium between microcomputed tomography and conventional histomorphometry. Calcif Tissue Int 1997; 61:493-498.
25. Yang J, Pham SM, Crabbe DL. High-resolution micro-CT evaluation of mid- to long-term effects of estrogen deficiency on rat trabecular bone. Acad Radiol 2003; 10:1153-1158.
26. Gallagher JC, Jerpbak CM, Jee WS etal. 1, 25-Dihydroxyvitamin D3: short- and long-term effects on bone and calcium metabolism in patients with postmenopausal osteoporosis. Proc Natl Acad Sci USA 1982; 79:3325-3329.
27. Maeda Y, Matsuyuki H, Shimano K etal. Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3. J Immunol 2007; 178:3437-3446.
28. Mihara M, Yoshida H. The involvement of interleukin-6 in the augmentation of immune response by immunologic adjuvants. In: Benvenuto A, ed. Immunologic adjuvant research. New York: Nova Science Publishers, 2009:105-112.
29. Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 2007; 8:1295-1301.
30. Lee SH, Lee SY, Lee YS etal. Higher circulating sphingosine 1-phosphate levels are associated with lower bone mineral density and higher bone resorption marker in humans. J Clin Endocrinol Metab 2012; 97:E1421-E1428.
31. De Klerck B, Carpentier I, Lories RJ etal. Enhanced osteoclast development in collagen-induced arthritis in interferon-gamma receptor knock-out mice as related to increased splenic CD11b+ myelopoiesis. Arthritis Res Ther 2004; 6:R220-R231.
32. De Benedetti F, Rucci N, Del Fattore A etal. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 2006; 54:3551-3563.
33. Keffer J, Probert L, Cazlaris H etal. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10:4025-4031.
34. Kotake S, Sato K, Kim KJ etal. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996; 11:88-95.
35. Garnero P, Thompson E, Woodworth T etal. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 2010; 62:33-43.
36. Karsdal MA, Schett G, Emery P etal. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Semin Arthritis Rheum 2012; 42:131-139.
37. Finzel S, Rech J, Schmidt S etal. Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study. Ann Rheum Dis 2013; 72:396-400.
38. Du J, Zeng C, Li Q etal. LPS and TNF-α induce expression of sphingosine-1-phosphate receptor-2 in human microvascular endothelial cells. Pathol Res Pract 2012; 208:82-88.